Physician profile
Nasimul Ghani
NPI 1558452565
$150.44
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.19 · 2021: $58.99 · 2022: $25.42 · 2024: $23.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $42.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.24 | 2022-2024 | |
| Ultragenyx Pharmaceutical INC. | $23.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.70 | 2021 | |
| Horizon Therapeutics Plc | $13.36 | 2021 | |
| Calliditas Therapeutics US INC. | $12.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasimul Ghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.